Skip to main content
. 2020 Apr 14;2020:5759265. doi: 10.1155/2020/5759265

Table 6.

Proportion of patients who had attained one or several treatment targets at the end of the 3-month tapentadol PR treatment.

Patients aged >65 years Patients aged ≤65 years
(a) Attainment of at least 50% reduction in pain intensity vs. baseline 67.6% (n = 725) 74.1% (n = 274)
(b) Attainment of intended pain intensity 65.1% (n = 725) 65% (n = 274)
(c) Attainment of additional individual treatment target 87.8% (n = 713) 91.5% (n = 272)
(d) Attainment of (b) and/or (c) (combined response rate) 87.9% (n = 728) 92% (n = 274)

n, number of patients with valid data; PR, prolonged release.